Receptor-Associated Protein (RAP), AmpTide(TM), may proved useful in treatment of cancers, including mesothelioma

Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP.OB), today announced its quarterly financial results. As a result of several research programs and operations overhead, expenses are anticipated to increase over the next twelve months.One of the programs involves research into a novel drug used to treat mesothelioma called AmpTide(TM).

AmpTide(TM) for Lung Cancer (Mesothelioma)

Raptor Pharmaceuticals has engineered a Receptor-Associated Protein (RAP) peptide, known as AmpTide(TM), to selectively bind a critical part of matriptase, a protein that is over- produced on lung cancer (mesothelioma) cells. Matriptase has been shown to enable tumor cells to aggressively invade surrounding tissues and thereby support tumor growth. In the fourth calendar quarter of 2007, Raptor Pharmaceuticals plans to test whether AmpTide(TM) interferes with the tumor-promoting activity of matriptase. Such interference may be useful in the treatment of a variety of cancers, including mesothelioma, which are known to over-produce matriptase.

About Raptor

Raptor Pharmaceuticals Corp.’s sole business is its 100% ownership of Raptor Pharmaceutical Inc., an early stage biotechnology research and development company which bioengineers novel drugs and drug-targeting platforms derived from the human receptor-associated protein (RAP) and related proteins.

Recent Posts in the Same Categories


Last update: March 06, 2014. 08:41:31 pm.